Stress urinary incontinence is a consistent health issue in female patients that is typically treated with surgical interventions. Clinicians have investigated less invasive treatments for this debilitating condition, but the question is whether they are safe and produce positive results.
In a recent study presented at the 2021 American Urological Association Annual Meeting, Melissa R. Kaufman, MD, PhD, FACS, and colleagues assess how the AMDC-USR technology mitigates primary SUI symptoms. Kaufman is a professor of urology and chief of the division of reconstructive urology and pelvic health at Vanderbilt University, Nashville, Tennessee.
This technology is truly a transformational opportunity for urology. This is the first regenerative option that's undergone such rigorous clinical evaluation. AMDC stands for autologous muscle derived cells and it's a product of muscle progenitor cells, which are stem cells that reside within the skeletal muscle that are stimulated by injury. These are terminally differentiated cells, and they originate from the biopsy that we harvest and the vastus lateralis of the thigh. They're grown in culture and then re-injected into the urethral sphincter and theorized to engraft to improve muscle function of the sphincter muscle that's causing the stress incontinence secondary to many of the sub quality of aging and prior surgeries. This product is in clinical trials for multiple interventions.
The one that we are discussing at this year's AUA is for stress urinary incontinence in women, but we also envision this being a product that can be used for men after prostatectomy; for fecal incontinence, in which there's ongoing studies; for under-active bladder, which is a very profound problem ranging across many areas; as well as for tongue dysphasia. The product that we're going to be discussing at AUA is developed for women with primary symptoms of stress incontinence. It's our most studied clinical indication. We've had over 600 women treated across the world since the initiation over a decade ago in our phase 1 and phase 2 trials. We're now embarking on our third phase 3 study. The AMDC product augments the urethral sphincter function that is deficient in women with stress incontinence, and as such, may serve as a really durable treatment for decades of time, maybe amenable to retreatment for a number of women. The product causes localized tissue changes that may engraft into the muscle and may cause a paracrine effect to bring in new growth factors. It may stimulate the progenitor cells that are there. In the studies that are presented at the AUA, one of the most interesting populations is a group of 115 women that were pooled across a number of studies that had prior surgeries for stress incontinence yet had recurrent or persistent symptoms following those surgeries. This is a population that have a life-altering condition who have already embarked upon prior surgeries and have very limited treatment options.
We all know that stress incontinence has an enormous impact on women's quality of life, and that ranges well beyond the direct symptoms that can be caused by pad use. It increases women's risk for depression, anxiety, decreased physical activity, productivity, and their daily activities at work. They suffer in healthy social and sexual relationships, and their day-to-day function really diminishes. When we look at that population have recurrent or persistent incontinence, these are women that progress in severity over time. What we found is that they had a higher level of bother on all our validated questionnaires to start with, because they had already embarked upon surgical therapies of which we all understand the pitfalls of. So, they have very limited treatment options and the adult muscle derived cells for sphincter regeneration represent a non-surgical means to provide very durable and effective support for these women who have suffered mightily from stress incontinence, oftentimes for long periods of time. They have not responded to what we would consider "gold standard" therapies for treatment.
We assume and hypothesize about what our outcomes are going to be in clinical trials, but interestingly, we've known from a lot of prior trials, both in this technology space for adult muscle derived cells and other stem cells and other incontinence measures, that determining the optimal levels of efficacy to discriminate well between your active agent versus placebo is a very complex endeavor. It's because I believe what happens is that women are now aware of their condition, and a clinical trial, sometimes there's mitigation and moderation of behaviors, so those conservative impacts are very powerful and we know that. They're often frontline therapies for both urgency and stress incontinence, so our placebo rates tend to be higher. That wasn't necessarily surprising in this trial, but what was novel was the remarkable efficacy in women who've undergone prior surgery with up to 30% demonstrating 0 to 1 stress leaks on their diaries. These were women that on their 3-day diaries, overall, had an average of 18 stress leaks. They could be between 3 and 45 to enroll in the trial, so to have 30% end up with what we would consider "cured situation" was very profound. It was quite a phenomenal success.
There's a group of women who have persistent recurrent incontinence following prior surgical interventions. This is truly an unmet medical need. These symptoms substantially impact daily functioning, impact quality of life. This is a well-tolerated outpatient procedure with excellent safety parameters. It is a single biopsy and a single injection, both of which take minutes of time. It is effective in this really challenging refractory population. And based on that evidence, data was submitted to the FDA because of the seriousness of this condition and Cook MyoSite was granted a regenerative medicine advanced therapy designation. This is a very powerful statement about not just the technology, but also this unmet need for our patients.
We are currently engaged in undertaking a phase 3 randomized placebo-controlled trial, which will be the third in the series for data presentation to the FDA to further define the technology and really optimize the population that responds best for treatment. We anticipated enrolling almost 300 women again. Almost 600 women today have engaged in these trials already, so this will be 300 more patients who will help all the women benefit from the technology and the future.
We are truly embarking at this moment on the next frontier in urology with these types of cellular therapies. It is an exceptionally gratifying opportunity to be able to potentially provide durable, safe treatments that actually reverse pathology and regenerate native function. The potential applications for this technology are very broad. The next decades of innovations in this space are going to be astounding and transformative to our current treatment strategies, and impact countless urology patients to really improve not just quality of life, but also quantity of life.
Reference
1. Kaufman MR, Peters KM, Chermansky CJ, et al. A double-blind, randomized, controlled trial comparing safety and efficacy of autologous muscle derived cells for urinary sphincter repair (AMDC-USR) with placebo (PBO) in women with stress urinary incontinence (SUI). Paper presented at 2021 American Urological Association Annual Meeting; September 10-13; virtual. Abstract PD06-01
Read the rest here:
Regenerative therapy linked to QOL benefit for patients with SUI - Urology Times
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
- NOT-AR-23-022: Request for Information on Themes for the NIAMS ... - National Institutes of Health (.gov) - December 3rd, 2023
- December 2023: Intramural Papers of the Month - Environmental Factor Newsletter - December 1st, 2023
- CNA Explains: What is cord blood banking and why do parents do it? - CNA - December 1st, 2023
- Regulation of myogenesis and adipogenesis by the electromagnetic ... - Nature.com - December 1st, 2023
- The effects of vitamin K on bone health - News-Medical.Net - December 1st, 2023
- Dr Hurwitz on Ongoing Investigations of the Use of CAR T-Cell ... - OncLive - December 1st, 2023
- Mitophagy in human health, ageing and disease - Nature.com - December 1st, 2023
- Adult Stem Cells - Stem Cells and the Future of Regenerative Medicine ... - November 29th, 2023
- Navigating The Regulatory Landscape Of Longevity Health Products ... - Mondaq News Alerts - November 29th, 2023
- MS breakthrough could lead to treatments that halt disease's ... - inews - November 29th, 2023
- Reprogramming tissue mechanically to promote wound healing - Phys.org - November 29th, 2023
- Latest Advances in Arthritis Diagnosis and Treatment at American ... - HealthDay - November 29th, 2023
- Sex-associated differences in frequencies and prognostic impact of ... - Nature.com - November 29th, 2023
- Hematologists Dive into the Current Treatment Landscape - OncLive - November 29th, 2023
- Team discovers protein crucial for B cell differentiation and antibodies - Phys.org - November 29th, 2023
- Science Talk - I survived cancer as a child and now I'm working to ... - The Institute of Cancer Research - November 29th, 2023
- First Edition: Nov. 29, 2023 - KFF Health News - November 29th, 2023
- Symptoms: Unilateral Hearing Loss and Tinnitus : The Hearing Journal - LWW Journals - November 29th, 2023
- Mitigation of sepsis-induced acute lung injury by BMSCs | IJN - Dove Medical Press - November 29th, 2023
- A Case of a Constricted Vessel: The Impact of Acute Myeloid ... - Cureus - November 29th, 2023
- Mum brushed off fatigue after having baby but fall sparked deadly diagnosis - The Mirror - November 29th, 2023
- How heritable is the epigenome? - Drug Discovery News - November 29th, 2023
- The Blueprint of Regeneration: Scientists Discover How to Turn Stem Cells Fate - Revyuh - November 27th, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - Marketscreener.com - November 27th, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - PharmiWeb.com - November 25th, 2023
- COVID-19 Pandemic's Adverse Effect on Bone Health in Young ... - HealthDay - November 25th, 2023
- Sickle cell breakthrough - The Indian Express - November 25th, 2023
- Wall thickness analysis method for judging the degree of lower ... - Nature.com - November 25th, 2023
- Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference - Yahoo Finance - November 23rd, 2023
- Disease Transmission and Diagnosis of Zika Virus - Cureus - November 23rd, 2023
- Gene-editing therapy for sickle cell earns conditional approval in UK - Sickle Cell Disease News - November 23rd, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - Newswire - November 21st, 2023
- Efficacy of ADSC-CM in Patients with Telogen Effluvium | SCCAA - Dove Medical Press - November 21st, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - PR Newswire - November 21st, 2023
- The Impact of CAR T Cell Therapy on Managing R/R LBCL - OncLive - November 21st, 2023
- Mansour bin Zayed witnesses inauguration of ADSCC Bone Marrow Transplant & Cellular Therapy Congress 2023 - ZAWYA - November 21st, 2023
- Listeria: Who is most susceptible? What are the Symptoms? What ... - Food Poison Journal - November 21st, 2023
- Scope Of Issued Patents May Be Limited By Prosecution Estoppel ... - Mondaq News Alerts - November 21st, 2023
- Qrons Announces the Addition of Professor Shiri Navon-Venezia to ... - StreetInsider.com - November 21st, 2023
- Financially strapped Athersys raises $10.4M - cleveland.com - November 19th, 2023
- From the India Today archives (2010) | How stem cells can save your life - India Today - November 19th, 2023
- Inactivation of the tumor suppressor gene Apc synergizes with H ... - Science - November 19th, 2023
- The Origins of Multiple Myeloma and Why it Matters - HealthTree For AML - Acute Myeloid Leukemia - November 19th, 2023
- Treatment Considerations With TROP2-Targeted Therapy - OncLive - November 19th, 2023
- Athersys narrows loss, raises $10.4 million during third quarter to ... - The Business Journals - November 17th, 2023
- Who was Dolly the Sheep and what happened to her? The story of ... - BBC Countryfile Magazine - November 17th, 2023
- UK first to approve CRISPR treatment for diseases: what you need to ... - Nature.com - November 17th, 2023
- 1st sickle cell patient to be given therapy restoring fetal hemoglobin - Sickle Cell Disease News - November 15th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates - Century - Benzinga - November 13th, 2023
- Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer - Yahoo Finance - November 11th, 2023
- Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in... - November 11th, 2023
- AAO 2023: Paul Runge and his ROP treatments in the Ukraine - Modern Retina - November 11th, 2023
- The Evolutionary Reasons We Are Drawn To Horror Movies and ... - Slashdot - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - GlobeNewswire - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 9th, 2023
- NYU Langone Health Performs World's First Whole-Eye & Partial ... - NYU Langone Health - November 9th, 2023
- BrainStorm to Announce Third Quarter 2023 Financial Results and ... - BioSpace - November 9th, 2023
- Can we cut cost and pain of IVF? Start-up CEO tries out own ... - Genetic Literacy Project - November 9th, 2023
- Jasper Therapeutics Reports Third Quarter 2023 Financial Results ... - BioSpace - November 9th, 2023
- Impaired neural stress resistance and loss of REST in bipolar ... - Nature.com - November 9th, 2023
- Functional genomics and systems biology in human neuroscience - Nature.com - November 9th, 2023
- Trial launched to test CAR T-cell therapy in dogs diagnosed with ... - EurekAlert - November 9th, 2023
- The-Gut's-Lasting-Impact-on-Severe-COVID-19-Immune-Response - Infectious Disease Special Edition - November 9th, 2023
- Emerging Cure for Sickle Cell on its Way to FDA Approval, Carries ... - Dallasweekly - November 7th, 2023
- The science works, but will we pay for it? - Irish Medical Times - November 7th, 2023
Recent Comments